Related Experiment Video

Updated: Oct 14, 2025

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

7.7K

The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas

Zhiyu Xi1, Pamela S Jones2, Masaaki Mikamoto2

  • 1Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

Frontiers in Endocrinology
|November 8, 2021
PubMed

Insights

Aggressive pituitary adenomas show higher immune checkpoint molecule expression. This suggests immune checkpoint inhibitors could be a potential therapy for these challenging brain tumors.

Area of Science:

  • Neuro-oncology
  • Immunology
  • Endocrinology

Background:

  • Pituitary adenomas are common intracranial neoplasms.
  • Aggressive subtypes pose therapeutic challenges.
  • Immune checkpoint inhibitors (ICIs) are effective cancer treatments.

Purpose of the Study:

  • Quantify immune checkpoint molecule expression in pituitary adenomas.
  • Compare expression between aggressive and non-aggressive tumors, and normal pituitary tissue.
  • Establish a rationale for ICI therapy in aggressive pituitary adenomas.

Main Methods:

  • Analyzed mRNA expression of PD-1, CTLA-4, PD-L1, PD-L2, CD80, and CD86.
  • Compared expression levels in human pituitary adenomas and normal pituitary glands.
  • Stratified analysis based on tumor aggressiveness.

Main Results:

  • Aggressive pituitary adenomas showed increased PD-L2, CD80, and CD86 mRNA expression compared to normal pituitary glands.
  • Aggressive tumors had significantly higher CD80 and CD86 levels than non-aggressive tumors.
  • PD-1 and CTLA-4 expression levels were not significantly different between groups.

Conclusions:

  • Elevated expression of PD-L2, CD80, and CD86 in aggressive pituitary adenomas supports further investigation.
  • Immune checkpoint inhibition therapy warrants study for aggressive pituitary adenomas.
  • This research provides a basis for developing novel therapeutic strategies.
Keywords:
aggressive pituitary adenomaimmune checkpoint blockadeimmune escapeimmunotherapypituitary adenoma

More Related Videos

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.1K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

789

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
731
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.0K